Author + information
- Zhu Jianbing and
- Junbo Ge
This study sought to examine the 30-day safety and efficacy of everolimus-eluting stent (EES) versus paclitaxel-eluting stent (PES) in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI).
We included data from 10 randomized controlled trials (RCT) involving 2,866 patients with respect to 3-year follow-up clinical outcomes. The incidence of myocardial infarction, cardiac death were the primary endpoints. Ischemia-driven target lesion revascularization and stent thrombosis were the secondary endpoints.
Compared with PES, EES resulted in decreased risk of myocardial infarction (2.8% vs. 4.8%, hazard ratio [HR]: 0.58, 95% CI: 0.45 to 0.82), cardiac death (4.8% vs. 6.8%, HR: 0.72, 95% CI: 0.58 to 0.79) and ischemia-driven target lesion failure (7.6% vs. 10.2%, HR: 0.69, 95% confidence interval [CI]: 0.54 to 0.90). Stent thrombosis (0.8% vs. 1.8%, HR: 0.52, 95% CI: 0.28 to 0.98) was also lower in EES compared with PES.
In patients with ACS undergoing PCI, EES is associated with reduction of myocardial infarction, cardiac death, ischemia-driven target lesion failure and stent thrombosis compared with PES.